Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Aug 26, 2021; 13(8): 1094-1111
Published online Aug 26, 2021. doi: 10.4252/wjsc.v13.i8.1094
Published online Aug 26, 2021. doi: 10.4252/wjsc.v13.i8.1094
Methods to produce induced pluripotent stem cell-derived mesenchymal stem cells: Mesenchymal stem cells from induced pluripotent stem cells
Victoria Dupuis, Faculté des Sciences et d’Ingénierie, Sorbonne Université, Paris 75252, France
Elisa Oltra, Department of Pathology, Universidad Católica de Valencia San Vicente Mártir, Valencia 46001, Spain
Elisa Oltra, Centro de Investigación Traslacional San Alberto Magno, Universidad Católica de Valencia San Vicente Mártir, Valencia 46001, Spain
Author contributions: Dupuis V elaborated the summary tables; Dupuis V and Oltra E designed the study and wrote the manuscript.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Elisa Oltra, PhD, Full Professor, Department of Pathology, Universidad Católica de Valencia San Vicente Mártir, C/Quevedo 2, Valencia 46001, Spain. elisa.oltra@ucv.es
Received: February 28, 2021
Peer-review started: February 28, 2021
First decision: April 19, 2021
Revised: May 3, 2021
Accepted: July 14, 2021
Article in press: July 14, 2021
Published online: August 26, 2021
Peer-review started: February 28, 2021
First decision: April 19, 2021
Revised: May 3, 2021
Accepted: July 14, 2021
Article in press: July 14, 2021
Published online: August 26, 2021
Core Tip
Core Tip: Heterogeneity of mesenchymal stem cell (MSC) quality might have hampered the robust success of stem cell clinical trials (CTs). The production of MSCs from a single homogeneous source (i.e. induced pluripotent stem cells, iPSCs) could elevate stem cell therapeutics standardization to unprecedented levels. However, a unique optimized procedure for large-scale production of MSCs, of homogenous quality, from iPSCs (iMSCs) is missing. Main methods, culture components, and common MSC markers to produce iMSCs are provided here as reference resources for the establishment of harmonized Good Manufacturing Procedures towards obtaining clinical-grade iMSCs with improved CT performance.